Recently, a fake news article circulated the internet claiming that scientists had proven that stopping the ageing process was not possible. In this brief article, we explain why this claim is patently false and based entirely upon a wilful misinterpretation of scientific data.
It was an honor to speak at MIT’s Broad Institute about some of my past and present synthetic biology research on redesigning bacteria and viruses to act as delivery systems for biomedicine! Video recording is now available! Here is a link which should take you to 1:40:18 when my talk starts:[ ]. My talk was part of the inaugural MIT Biosummit (https://mitbiosummit.com/), a forward-looking conference which this year focused on tackling challenges at the interface of climate change and health sciences. #futureofmedicine #future #biotech #mit Thank you Ryan Robinson for helping to organize this conference and for giving your own excellent talk!
Recording of the MIT Club of Boston 2023 BioSummit: Human Health 2050 held at the Broad Institute on April 27, 2023. Note: Although the video is almost 6 hours long, you can rapidly navigate and skip to a particular speaker or session by scrubbing along the video timeline (in Chrome or Edge) or using the time markers listed below in blue (in all browsers). You can also use chapter browsing in the YouTube app on platforms where it is available.
Insulin-mTOR signaling drives anabolic growth in organismal development, while its late-life antagonistic pleiotropy affects aging and compromises lifespan across animal phylogeny. Here we identify LPD-3 as a megaprotein that orchestrates the tempo of insulin-mTOR signaling during C. elegans aging. We find that an agonist insulin INS-7 is drastically over-produced and shortens lifespan in lpd-3 mutants, a C. elegans model of human Alkuraya-Kučinskas syndrome. LPD-3 forms a bridge-like tunnel megaprotein to facilitate phospholipid trafficking to plasma membrane. Lipidomic profiling reveals increased abundance of hexaceramide species in lpd-3 mutants, accompanied by up-regulation of hexaceramide biosynthetic enzymes, including HYL-1 (Homolog of Yeast Longevity). Reducing HYL-1 activity decreases INS-7 levels and rescues the shortened lifespan of lpd-3 mutants through insulin receptor/DAF-2 and mTOR/LET-363. LPD-3 antagonizes SINH-1, a key mTORC2 component, and reduces protein abundance with age in wild type animals. We propose that LPD-3 acts as a megaprotein brake for aging and its age-dependent decline restricts lifespan through the sphingolipid-hexaceramide and insulin-mTOR pathways.
The authors have declared no competing interest.
As one of the OMICS in systems biology, metabolomics defines the metabolome and simultaneously quantifies numerous metabolites that are final or intermediate products and effectors of upstream biological processes. Metabolomics provides accurate information that helps determine the physiological steady state and biochemical changes during the aging process. To date, reference values of metabolites across the adult lifespan, especially among ethnicity groups, are lacking. The “normal” reference values according to age, sex, and race allow the characterization of whether an individual or a group deviates metabolically from normal aging, encompass a fundamental element in any study aimed at understanding mechanisms at the interface between aging and diseases.
Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD
Discount Links:
NAD+ Quantification: https://www.jinfiniti.com/intracellular-nad-test/
Use Code: ConquerAging At Checkout.
Green Tea: https://www.ochaandco.com/?ref=conqueraging.
Oral Microbiome: https://www.bristlehealth.com/?ref=michaellustgarten.
Researchers almost doubled the lifespan of yeast cells by genetically rewiring the circuit that controls aging in a new proof-of-concept study.
A recent study demonstrated that non-invasive stimulation of the right cerebellum led to improvements in episodic memory performance in healthy elderly individuals, at the end of a 12-day neurostimulation program, and also at the point of a 4-month follow-up.
The steady increase in average life expectancy poses significant challenges to individuals, families, and societies across multiple dimensions. Estimating that by 2050 one in every six individuals will be over the age of 65, the study of aging and its association with cognitive decline, neurodegenerative diseases and overall frailty is becoming increasingly important.
Therefore, it has been an important goals of neurosciences research to understand the relationship between the aging brain and episodic memory deficits and to develop interventions to mitigate the age-related decline in our ability to remember personal past events (episodic memory).
People’s ability to regenerate bones declines with age and is further decreased by diseases such as osteoporosis. To help the aging population, researchers are looking for new therapies that improve bone regeneration.
Now, an interdisciplinary team of researchers from the Biotechnology Center (BIOTEC) and the Medical Faculty of TU Dresden along with a group from Max Bergmann Center of Biomaterials (MBC) developed novel bio-inspired molecules that enhance bone regeneration in mice. The results were published in the journal Biomaterials.
As people age, their ability to regenerate bones decreases. Fractures take longer to heal and diseases like osteoporosis only add to it. This represents a serious health challenge to the aging population and an increasing socioeconomic burden for the society. To help combat this issue, researchers are looking for new therapeutic approaches that can improve bone regeneration.
People typically think of food as calories, energy and sustenance. However, the latest evidence suggests that food also “talks” to our genome, which is the genetic blueprint that directs the way the body functions down to the cellular level.
This communication between food and genes may affect your health, physiology and longevity. The idea that food delivers important messages to an animal’s genome is the focus of a field known as nutrigenomics. This is a discipline still in its infancy, and many questions remain cloaked in mystery. Yet already, we researchers have learned a great deal about how food components affect the genome.
I am a molecular biologist who researches the interactions among food, genes and brains in the effort to better understand how food messages affect our biology. The efforts of scientists to decipher this transmission of information could one day result in healthier and happier lives for all of us. But until then, has unmasked at least one important fact: Our relationship with food is far more intimate than we ever imagined.
In March 2023, MIT Technology Review revealed that Sam Altman, the CEO of OpenAI (ChatGPT), was the mystery investor behind the $180 million investment into stealth startup Retro Biosciences, a biotech company with the ambition of “adding 10 years to the human lifespan.” This investment marks the latest tech entrepreneur expressing their interest in longevity science and a new connection with innovative AI technology.
According to February 2023 reports, AI is continuing to gain traction in healthcare applications. Currently, the market is estimated at $14.6 billion (USD) with a compound annual growth rate (CAGR) of 47.6%, with solutions spread across various healthcare fields, such as patient data and risk analysis, precision medicine, cybersecurity, lifestyle management, and drug discovery.
The increasing convergence of AI technology and longevity science is sparking advancements in the sector, with established businesses, start-ups, and researchers utilizing the technology. Most recently, scientists explored how ChatGPT, an AI-based language model, was able to predict Alzheimer’s in 80% of cases when analyzing speech. However, it is not the only implementation.
